On October 2, 2023, Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine for their groundbreaking research on modified mRNA technology.

The Penn Institute for RNA Innovation, led by Weissman, has significantly expanded, tripling in size within a year to support ongoing mRNA research.

To further advance RNA research, the Penn Institute has received an $18 million grant from the National Science Foundation, which will incorporate artificial intelligence into their studies.

Current research at the institute focuses on developing new mRNA vaccines for various diseases, including influenza, HIV, and Clostridioides difficile (C. diff).

Recent developments in mRNA technology include vaccines for herpes simplex virus 2 (HSV2) and Lyme disease, with clinical trials currently underway.

Weissman and his colleagues are also exploring the application of mRNA technology in cancer treatment by targeting tumor defenses.

The team is working towards creating 'pan' vaccines that could prevent multiple strains of viruses, potentially revolutionizing vaccine administration.

In addition to human health, Penn's School of Veterinary Medicine is collaborating with the RNA Institute to study mRNA vaccines in animals, aiming to prevent animal pandemics and improve food security.

International scientists, including those from Uganda, are visiting Penn to learn about mRNA vaccine development, which could enhance vaccine access in their home countries.

This ongoing research underscores the transformative potential of mRNA technology in both human and veterinary medicine, with real-world applications already saving lives.